Výsledky vyhledávání

Zanubrutinib plus obinutuzumab (ZO) versus obinutuzumab (O) monotherapy in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the phase 2 randomized ROSEWOOD trial

Autor: Pier Luigi Zinzani, Jiří Mayer, Rebecca Auer, Fontanet Bijou, Ana C. de Oliveira, Christopher Flowers, Michele Merli, Krimo Bouabdallah, Peter S. Ganly, Roderick Johnson, Sam Yuen, Ed Kingsley, Gayane Tumyan, Sarit E. Assouline, Elena Ivanova, Pil Kim, Jane Huang, Richard Delarue, Judith Trotman

Publikováno v: Journal of Clinical Oncology. 40:7510-7510

7510 Background: FL is the most common type of indolent non-Hodgkin lymphoma. Approved treatment options are limited for pts with R/R FL. In a phase 1b trial ( Blood Adv. 2020;4(19):4802-4811), ZO was found to be tolerable and associated with early s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d313293cc8148c353bccda89ca51a6dc
https://doi.org/10.1200/jco.2022.40.16_suppl.7510

Zobrazit plný text záznamu

Phase 3 randomized study of loncastuximab tesirine in combination with rituximab (Lonca-R) versus immunochemotherapy in patients with R/R DLBCL (LOTIS-5)

Autor: Mehdi Hamadani, Yuliya Linhares, Mitul Gandhi, Michael Chung, Helena Adamis, David Ungar, Carmelo Carlo-Stella, Ed Kingsley, Julien Depaus, Sylvia Snauwaert, Michal Kwiatek, Javier López-Jiménez

Publikováno v: Journal of Clinical Oncology. 40:TPS7591-TPS7591

TPS7591 Background: Patients (pts) with refractory or relapsed (R/R) diffuse large B-cell lymphoma (DLBCL) have poor outcomes with standard treatment. Loncastuximab tesirine (loncastuximab tesirine-lpyl; Lonca), an antibody-drug conjugate (ADC) compr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fd64a9af59b824eb5ab8196080b5be47
https://doi.org/10.1200/jco.2022.40.16_suppl.tps7591

Zobrazit plný text záznamu

Preliminary results of the phase 2 study of zanubrutinib in patients with previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib

Autor: Syed F. Zafar, Troy H. Guthrie, Jennifer L. Cultrera, Mazyar Shadman, Habte A. Yimer, Moshe Yair Levy, Ian W. Flinn, Aileen Cohen, Jeff Porter Sharman, Jamal Misleh, Jane Huang, Shibao Feng, Benjamin Bruce Freeman, Dih-Yih Chen, Arvind Chaudhry, Ed Kingsley, John M. Burke, Subramanya S. Rao, Ryan F. Porter

Publikováno v: Journal of Clinical Oncology. 39:e19506-e19506

e19506 Background: Many patients (pts) with B-cell malignancies require continuous treatment with Bruton tyrosine kinase inhibitors (BTKi). Adverse events (AEs) are a common reason for ibrutinib (ibr) or acalabrutinib (acala) discontinuation. Early d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::06993358b2b4e978d7168095cf4c1c80
https://doi.org/10.1200/jco.2021.39.15_suppl.e19506

Zobrazit plný text záznamu

LETTERS

Autor: Sarah L. Smith, Ed Kingsley, Gerry L. Ensley, Douglass F. Taber, Gary Rummler

Publikováno v: Dialogue: A Journal of Mormon Thought. 31:iv-xv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2396be78f57ef29aaa77cb2a22751b08
https://doi.org/10.2307/45226441

Zobrazit plný text záznamu

The toxicity of metabolites of sodium valproate in cultured hepatocytes

Autor: Ed Kingsley, Rowan Tweedale, Keith G. Tolman, Phillip D. Gray

Publikováno v: Journal of clinical pharmacology. 23(4)

Sodium valproate is hepatotoxic in both humans and rat hepatocytes. The toxicity is dose related and frequently associated with simultaneous ingestion of drugs which induce the drug metabolizing system. For these reasons, metabolites of sodium valpro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4113583b651d720fd12eb386e8ab3ad
https://pubmed.ncbi.nlm.nih.gov/6408143

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání